title: Ethics of continuing to provide a drug on an open-label extension study for an "unapproved indication".
authors.affiliation: a Johns Hopkins Berman Institute of Bioethics and Johns Hopkins Bloomberg School of Public Health.
authors.forename: Holly A
authors.initials: HA
authors.lastname: Taylor
authors.forename: Ellen
authors.initials: E
authors.lastname: Kuwana
authors.forename: Benjamin S
authors.initials: BS
authors.lastname: Wilfond
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000191:economics*; D001315:Australia; D002170:Canada; D011307:Drug Prescriptions / Q000592:standards*; D032984:Ethics, Research; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D015337:Multicenter Studies as Topic / Q000941:ethics; D056687:Off-Label Use / Q000941:ethics*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics*; D012108:Research Personnel / Q000941:ethics; D016896:Treatment Outcome; D014481:United States; D016138:Walking
chemical_list: D000959:Antihypertensive Agents